Related Experiment Video
Updated: Feb 11, 2026

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
Hepatitis B Vaccination Effective in Children Exposed to Anti-Tumour Necrosis Factor Alpha in Utero
Alison de Lima1, Shannon L Kanis1, Johanna C Escher2
1Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, the Netherlands.
Insights
Infants exposed to tumor necrosis factor [TNF] alpha inhibitors in utero demonstrate effective hepatitis B virus [HBV] vaccination responses. Post-vaccination anti-HB levels were comparable between exposed and unexposed children, indicating successful immunization.
Area of Science:
- Immunology
- Pediatrics
- Vaccinology
Background:
- Neonates exposed to tumor necrosis factor [TNF] alpha inhibitors in utero can have detectable drug levels persisting for up to a year.
- The hepatitis B virus [HBV] vaccine is a routine childhood immunization in the Netherlands.
- Adults on anti-TNF therapy may exhibit suboptimal responses to HBV vaccination.
Purpose of the Study:
- To compare anti-HB levels in children exposed to anti-TNF therapy in utero with those of unexposed children.
- To assess the efficacy of routine Dutch HBV vaccination in neonates with in utero anti-TNF exposure.
Main Methods:
- A cross-sectional, controlled cohort study was conducted between 2014 and 2017.
- Participants included pregnant women with inflammatory bowel disease [IBD] on anti-TNF therapy and their neonates, compared to a control group.
- Anti-HB levels were measured via enzyme-linked immunosorbent assay one month after the final HBV vaccination dose.
Main Results:
- No significant difference in anti-HB levels was observed at 12 months between the anti-TNF-exposed group (>1000 IU/l) and the control group (>1000 IU/l) [p = 0.59].
- All children in both groups achieved successful HBV immunization, defined as anti-HB levels > 10 IU/l.
- Median anti-TNF levels in cord blood were 9.0 µg/ml for infliximab and 0.4 µg/ml for adalimumab; no differences in birth or health outcomes were noted.
Conclusions:
- Neonates with in utero exposure to anti-TNF agents can be effectively immunized against hepatitis B virus.
- Routine HBV vaccination is successful in children born with detectable anti-TNF drug levels.
Introduction:
Neonates exposed to tumour necrosis factor [TNF] alpha inhibitors in utero are born with detectable drug levels which can still be detected throughout the first year of life. Since 2011, the hepatitis B virus [HBV] vaccine is routinely administered to all newborns in the Netherlands. Adults treated with anti-TNF have been reported to respond inadequately to the HBV vaccine. The aim of this study was to compare anti-HB levels in anti-TNF-exposed children with non-exposed children following routine Dutch HBV vaccination.
Methods:
We performed a cross-sectional, controlled cohort study from 2014 to 2017 in a single, tertiary referral centre. Pregnant women treated with anti-TNF for inflammatory bowel disease [IBD] and their subsequent children were recruited from the IBD preconception outpatient clinic. Pregnant women not treated with anti-TNF for IBD and their subsequent children were eligible as controls. Adherence to the Dutch National Vaccination Programme was mandatory for participation in this study. A venous blood sample was obtained 1 month after final HBV vaccination. Anti-HB levels were measured by enzyme-linked immunosorbent assay.
Results:
Anti-HB levels at 12 months did not differ between the anti-TNF-exposed [n = 15] and the control group [n = 12] [> 1000 IU/l vs > 1000 IU/l, p = 0.59]. All children were successfully immunized against HBV, defined as anti-HB > 10 IU/l. Median anti-TNF levels determined in cord blood at birth were 9.0 µg/ml [interquartile range: 3.0-15.0 µg/ml] for infliximab and 0.4. µg/ml [interquartile range: 0.3-0.6 µg/ml] for adalimumab. There were no differences in general birth and health outcomes.
Conclusion:
Children born with detectable anti-TNF levels can be effectively vaccinated against HBV.
Related Concept Videos
Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Vaccinations
Hepatic Drug Excretion: Influencing Factors
Biological Effects of Radiation
Factors Affecting Dissolution: Particle Size and Effective Surface Area
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

